)
Pharma major Lupin aims to focus extensively on two therapeutic areas of dermatology and respiratory and expects 25-30 product approvals in FY 2016, according to brokerage Barclays Equity Research.
"Approvals in the US continue to be a work-in-progress although Lupin management believes that the number of approvals should improve sequentially going ahead.
"Management highlighted that the company is expecting 25-30 approvals in FY 2016 with the number for FY 2017 likely to be even higher than this," British brokerage Barclays Equity Research said in its report here.
With 10 final approvals in the past 12 months, Lupin has led the Indian pharma peers on this metric, Barclays Research Analyst Balaji Prasad said after meeting with the Lupin's senior management to discuss issues and the long-term strategy.
The company management also reiterated its aspiration of $5 billion in sales by FY2018 with inorganic growth being a key component, too.
Inorganic sales target of $1 billion of the revenue guidance of $5 billion in the next five years likely to be driven by new market entries in Brazil, Russia , Prasad said.
The company's brand acquisitions in the US remains a key focus area with the company having looked at 30-40 brands.
